Search
Remestemcel-L
go.drugbank.com/drugs/DB13973ApprovedInvestigationalWithdrawnof the recipients [A31818]. aGvHD is often characterized by the presence of inflammatory cascades through signalling of activated T cells. … [L11022] Remestemcel-L was later approved by the FDA on December 18, 2024.
Tenofovir alafenamide
go.drugbank.com/drugs/DB09299ApprovedInvestigational[A178060] Both of these prodrugs were first created to cover the polar phosphonic acid group on tenofovir by using a novel oxycarbonyloxymethyl linkers to improve the oral bioavailability and intestinal … [T239] Tenofovir alafenamide is an alanine ester form characterized for presenting low systemic levels but high intracellular concentration.
Difenoxin
go.drugbank.com/drugs/DB01501ApprovedIllicitIt is approved by the FDA to treat acute and chronic diarrhea. … It works mostly in the periphery and activates opioid receptors in the intestine rather than the central nervous system (CNS). [3] Difenoxin is also closely related to loperamide, but unlike loperamide
Ephedrine
go.drugbank.com/drugs/DB01364ApprovedInvestigational[L12972] Ephedrine and [phenylephrine] are still used to treat hypotension, but their use in other indications has decreased due to the development of more selective adrenergic agonists.
Products: T-drene 1, Ultra T-M - TabletHydromorphone
go.drugbank.com/drugs/DB00327ApprovedIllicitInvestigationalDue to these modifications, it presents a very high potency and comparable side effect profile to the parent compound. … [A176495] The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984.[L5795]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeCarbamazepine
go.drugbank.com/drugs/DB00564ApprovedInvestigationalIt was initially approved by the FDA in 1965.[A180301] Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. … Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia.
International brands: ActebralCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeEfanesoctocog alfa
go.drugbank.com/drugs/DB16662ApprovedInvestigationalEndogenous VWF protects FVIII from degradation but also sets a half-life of approximately 15 to 19 h. … [A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414]
Crotalus adamanteus antivenin
go.drugbank.com/drugs/DB13893ApprovedIt is intravenously administered to limit systemic toxicity [FDA label]. … The majority of people bitten are males and about 50% occur in the age group of 18 to 28 [F116].
Valoctocogene roxaparvovec
go.drugbank.com/drugs/DB15561ApprovedInvestigationalWithdrawn[L43292] Hemophilia A treatments such as prophylactic regimens of exogenous factor VIII or [emicizumab] improve the clinical outcomes of patients but do not eliminate breakthrough bleeding. … [L43282] The expression of hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and increase the levels of active factor VIII in blood.
Ipratropium
go.drugbank.com/drugs/DB00332ApprovedInvestigational[A176957] Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the combination product of ipratropium and [albuterol
Categories: Agents to Treat Airway Disease